News >

Radiofrequency Ablation Improves Survival Over SBRT in Localized HCC

Jason Harris
Published: Wednesday, Jan 24, 2018

Anne M. Covey, MD

Anne M. Covey, MD
Radiofrequency ablation (RFA) was associated with superior 5-year overall survival (OS) compared with stereotactic body radiotherapy (SBRT) for patients with localized hepatocellular carcinoma, according to an observational study published in the Journal of Clinical Oncology. 1

“Earlier detection due to improved screening programs will likely increase the number of patients with small tumors eligible for RFA and SBRT,” she said. “Exciting new technology in ablation, including improved assessment of treatment margins and the ability to create larger ablation zones, and in radiation oncology, including proton therapy, continue to improve the outlook for patients with hepatocellular carcinoma.”


  1. Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: Analysis of the national cancer database [published online January 12, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.75.3228.
  2. Covey AM. Survival following radiofrequency ablation versus stereotactic body radiotherapy for early-stage hepatocellular carcinoma. J Clin Oncol [podcast]. doi: 10.1200/JCO.2017.75.3228.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication